ACRO Launching New Video Series With Health Coalition Leaders
The Association of Clinical Research Organizations is introducing a new series of videos featuring the leaders of prominent healthcare interest groups.
The first two videos feature Ladd Wiley, Executive Director of the Alliance for a Stronger FDA, and Michael Reilly, Executive Director of the Alliance for Safe Biologic Medicines.
“ACRO participates in several alliances and coalitions to help amplify our message about the importance of clinical research,” said John Lewis, Vice President of Public Affairs. “We thank Ladd and Michael for helping us kick-off this series by discussing the important topics of adequate funding for the FDA and regulatory matters surrounding biosimilars. We plan several additional videos covering issues such as incentives for medical research, regenerative medicine, comparative effectiveness research and the business environment for life sciences in India.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
